Novel Insights into Mesothelioma Biology and Implications for Therapy

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2017 Jul 26

PMID 28740119

Citations 183

Authors

Timothy A Yap

Joachim G Aerts

Sanjay Popat

Dean A Fennell

Affiliations

Soon will be listed here.

Abstract

Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.

Citing Articles

Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review).

Andreikos D, Spandidos D, Georgakopoulou V Int J Oncol. 2025; 66(3).

PMID: 39981889 PMC: 11844339. DOI: 10.3892/ijo.2025.5729.

CD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study.

Aoki Y, Arimura K, Hiroshima K, Sato Y, Kondo M, Tagaya E J Thorac Dis. 2025; 17(1):109-120.

PMID: 39975728 PMC: 11833596. DOI: 10.21037/jtd-24-1598.

Case report: Clonal evolution analysis of a rare case of meningioma lung metastases identifies actionable alterations in matched longitudinal tumour samples.

Cosgrove N, Fitzpatrick O, Grogan L, Hennessy B, Furney S, Toomey S Front Oncol. 2025; 14:1483126.

PMID: 39935847 PMC: 11810962. DOI: 10.3389/fonc.2024.1483126.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system.

Lang W, He Y, Hou C, Li H, Jiang Q, Mei L Front Pharmacol. 2025; 15():1402423.

PMID: 39840092 PMC: 11746052. DOI: 10.3389/fphar.2024.1402423.

Myeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice.

Shindyapin V, Gubernatorova E, Gorshkova E, Chicherina N, Sysonov F, Yakovleva A Cells. 2025; 13(24.

PMID: 39768223 PMC: 11675005. DOI: 10.3390/cells13242135.

References

Farioli A, Ottone M, Morganti A, Compagnone G, Romani F, Cammelli S . Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med. 2016; 5(5):950-9. PMC: 4864824. DOI: 10.1002/cam4.656. View

Wagner J, SLEGGS C, Marchand P . Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960; 17:260-71. PMC: 1038078. DOI: 10.1136/oem.17.4.260. View

Bott M, Brevet M, Taylor B, Shimizu S, Ito T, Wang L . The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011; 43(7):668-72. PMC: 4643098. DOI: 10.1038/ng.855. View

Frizelle S, Grim J, Zhou J, Gupta P, Curiel D, Geradts J . Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene. 1998; 16(24):3087-95. DOI: 10.1038/sj.onc.1201870. View

Altomare D, Vaslet C, Skele K, De Rienzo A, Devarajan K, Jhanwar S . A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005; 65(18):8090-5. DOI: 10.1158/0008-5472.CAN-05-2312. View

Yap T, Omlin A, de Bono J . Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol. 2013; 31(12):1592-605. DOI: 10.1200/JCO.2011.37.6418. View

Jensen D, Proctor M, Marquis S, Gardner H, Ha S, Chodosh L . BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998; 16(9):1097-112. DOI: 10.1038/sj.onc.1201861. View

Testa J, Cheung M, Pei J, Below J, Tan Y, Sementino E . Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43(10):1022-5. PMC: 3184199. DOI: 10.1038/ng.912. View

NEWHOUSE M, Thompson H . Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med. 1965; 22(4):261-9. PMC: 1069377. DOI: 10.1136/oem.22.4.261. View

10.

Dammeijer F, Lievense L, Veerman G, Hoogsteden H, Hegmans J, Arends L . Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. 2016; 34(26):3204-12. DOI: 10.1200/JCO.2015.66.3955. View

11.

Coussens L, Zitvogel L, Palucka A . Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science. 2013; 339(6117):286-91. PMC: 3591506. DOI: 10.1126/science.1232227. View

12.

Dogan A, Baris Y, Dogan M, Emri S, Steele I, Elmishad A . Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006; 66(10):5063-8. DOI: 10.1158/0008-5472.CAN-05-4642. View

13.

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026):1405-1414. DOI: 10.1016/S0140-6736(15)01238-6. View

14.

Sterman D, Alley E, Stevenson J, Friedberg J, Metzger S, Recio A . Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clin Cancer Res. 2016; 22(15):3791-800. PMC: 4970934. DOI: 10.1158/1078-0432.CCR-15-2133. View

15.

Pott F, Ziem U, Reiffer F, Huth F, Ernst H, Mohr U . Carcinogenicity studies on fibres, metal compounds, and some other dusts in rats. Exp Pathol. 1987; 32(3):129-52. DOI: 10.1016/s0232-1513(87)80044-0. View

16.

Artvinli M, Baris Y . Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epidemiologic study. J Natl Cancer Inst. 1979; 63(1):17-22. View

17.

Bianchi C, Bianchi T . Global mesothelioma epidemic: Trend and features. Indian J Occup Environ Med. 2015; 18(2):82-8. PMC: 4280782. DOI: 10.4103/0019-5278.146897. View

18.

Stott F, Bates S, James M, McConnell B, Starborg M, Brookes S . The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-14. PMC: 1170828. DOI: 10.1093/emboj/17.17.5001. View

19.

Huang S, Jaurand M, Kamp D, Whysner J, Hei T . Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev. 2011; 14(1-4):179-245. PMC: 3118525. DOI: 10.1080/10937404.2011.556051. View

20.

Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D . Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013; 14(11):1104-1111. DOI: 10.1016/S1470-2045(13)70381-4. View